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MYELOID NEOPLASIA
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Recent evidence suggests chronic my-
eloid leukemia (CML) stem cells are insen-
sitive to kinase inhibitors and respon-
sible for minimal residual disease in
treated patients. We investigated whether
CML stem cells, in a transgenic mouse
model of CML-like disease or derived
from patients, are dependent on Bcr-Abl.
In the transgenic model, after retransplan-
tation, donor-derived CML stem cells in
which Bcr-Abl expression had been in-
duced and subsequently shut off were
able to persist in vivo and reinitiate leuke-
mia in secondary recipients on Bcr-Abl
reexpression. Bcr-Abl knockdown in hu-
man CD34CML cells cultured for 12 days
in physiologic growth factors achieved
partial inhibition of Bcr-Abl and down-
stream targets p-CrkL and p-STAT5, inhi-
bition of proliferation and colony forming
cells, but no reduction of input cells. The
addition of dasatinib further inhibited
p-CrkL and p-STAT5, yet only reduced
input cells by 50%. Complete growth fac-
tor withdrawal plus dasatinib further re-
duced input cells to 10%; however, the
surviving fraction was enriched for primi-
tive leukemic cells capable of growth in a
long-term culture-initiating cell assay and
expansion on removal of dasatinib and
addition of growth factors. Together, these
data suggest that CML stem cell survival
is Bcr-Abl kinase independent and
suggest curative approaches in CML
must focus on kinase-independent
mechanisms of resistance. (Blood. 2012;
119(6):1501-1510)
Introduction
In chronic myeloid leukemia (CML), the malignant clone is driven
by the oncogene Bcr-Abl. Although there is strong evidence that
Bcr-Abl is sufficient to induce CML-like disease in transduction/
transplantation and transgenic murine models,1,2 it is less clear that
Bcr-Abl is always the first hit in CML in humans or that the disease
in chronic phase is maintained by Bcr-Abl as the only driver
mutation, rather than by additional genetic and/or epigenetic
changes, as has been shown recently for Philadelphia-positive and
-negative acute lymphoblastic leukemia.3,4 Therefore, comparisons
between mouse models and primary CML should be interpreted
with caution. In primary CML studies, kinase inhibitors, imatinib,5
dasatinib,6 or nilotinib7 induced high rates of apoptosis. Similarly,
in transduction/transplantation1 and transgenic1,2,8 murine models
of Ph B-cell leukemia or CML, inhibition of Bcr-Abl kinase, by
kinase inhibitors or by switching off transgene expression, resulted
in proliferation arrest, apoptosis, and complete remissions.
Kinase inhibitors have transformed the natural history of CML
by inducing cytogenetic and molecular responses in the majority of
patients in chronic phase9 and resulting in transient deep responses
in many cases of advanced disease.10 A proportion of CML cases
develops drug resistance, with the incidence increasing in more
advanced disease.11 In most cases, the leukemic cells continue to
express Bcr-Abl and often retain their dependence on the onco-
gene. For example, where the underlying mechanism for drug
resistance is expansion of a clone expressing a Bcr-Abl kinase
domain mutation resulting in imatinib resistance, the leukemic cells
retain sensitivity to second-generation kinase inhibitors.7,12
Those working on CML now believe we are on a “pathway to
cure”; however, this belief is tempered by the insensitivity of CML
stem cells to kinase inhibitors. We have consistently demonstrated
that kinase inhibitors, imatinib,13,14 nilotinib,15,16 dasatinib17,18 and
bosutinib,19 although exhibiting potent antiproliferative effects, are
only weak inducers of apoptosis in CML stem and progenitor cells.
In primitive stem/progenitor cells (CD3438) harvested from
CML patients in durable complete cytogenetic response over
5 years, Bcr-Abl transcripts show no suggestion of a downward
trend over time.20 Furthermore, genomic PCR and PCR on
individual long-term culture-initiating cell (LTC-IC) colonies re-
veals that CML patients on imatinib who achieve complete
molecular response remain Bcr-Abl positive.21,22 These in vitro and
in vivo results, derived from primary human CML stem and
progenitor cells, at least hint that CML stem cells may not be
“oncogene addicted.” However, in these studies, no conclusive
evidence was provided that Bcr-Abl activity had been fully
suppressed in the surviving cells and in particular in leukemic stem
cells with repopulating potential, with many groups focused on
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issues of drug transport23,24 and more potent kinase inhibitors.15-19
These data have recently been strengthened by a carefully con-
ducted study which concluded that primary CML stem cells are
insensitive to imatinib despite inhibition of Bcr-Abl.25 Similarly, in
transgenic mice, multiple rounds of induction and reversion of
Bcr-Abl are possible,2,8 suggesting long-term persistence of leuke-
mic stem cells. However, as these studies were performed in
primary recipients only, there was no proof that transplantable stem
cells were responsible for disease reinitiation. To address these
critical points, we used complementary in vivo and in vitro
approaches to determine whether Bcr-Abl activity is required for
the survival of transplantable murine CML-like and primary human
CML stem cells and conclude that this critical population is
independent of Bcr-Abl kinase activity for survival.
Methods
Reagents
Dasatinib was obtained from Bristol-Myers Squibb (BMS). Stock solution
(10 mg/mL) in DMSO (Sigma-Aldrich) was prepared and stored in aliquots
at20°C.
Primary cell samples
After informed consent, CD34 cells were enriched from CML chronic-
phase samples at diagnosis and non-CML controls and cryopreserved.17
In vitro cell culture
HT1080 and 293FT cells were cultured in DMEM, K562, KCL22, and
BaF3 cells in RPMI 1640 medium, supplemented with 1% (vol/vol)
penicillin/streptomycin (10 000 g/mL/10 000 U/mL), 1% L-glutamine,
and 10% (vol/vol) FCS (all Invitrogen). IL-3 (10 ng/mL; StemCell Technolo-
gies) was added to parental BaF3 cells. Primary CML cells were cultured in
serum-free medium,17 supplemented with a high growth factor cocktail,
100 ng/mL Flt-3 ligand and SCF, and 20 ng/mL each of IL-3, IL-6
(StemCell Technologies) and G-CSF (Chugai Pharma Europe Ltd), growth
factor cocktail for transduction, 50 ng/mL SCF, 100 ng/mL thrombopoietin
(TPO) and Flt-3 ligand, physiologic growth factor cocktail, 0.2 ng/mL SCF,
GM-CSF, and MIP-, 1.0 ng/mL G-CSF and IL-6, 0.05 ng/mL Leukemia
inhibitory factor (LIF; StemCell Technologies) or with no added growth
factors. Primary mouse cells were cultured in serum-free expansion
medium (SFEM) supplemented with 10 ng/mL IL-3, IL-6, and mSCF
(StemCell Technologies).
FISH
FISH was performed as previously described.17
Lentivirus production
The pHIV7-GFP transfer vector containing the shRNA expression cassette
specific for 2 different splice forms of Bcr-Abl, pCMV-VSV-G and
pCMV-Hiv1, were provided by Dr John Rossi (Dept of Molecular and
Cellular Biology, Beckman Institute of City Hope, Duarte, CA).26 Trans-
duction of K562 or KCL22 was performed at a MOI 1-10 with 70%-95%
of the cells expressing GFP after 48 hours. Primary human CD34 cells
were preincubated on retronectin (8 g/cm2) in medium containing growth
factor cocktail for transduction for 2 days. Concentrated lentivirus was
added twice for 24 hours at MOI 40. Forty-eight hours later, cells were
FACS-sorted on GFP and cultured in medium containing physiologic
growth factors.
Western blotting and flow cytometry
Western blotting was performed17 using Abs against Bcr-Abl/Abl, p-CrkL,
p-STAT5, Tubulin (Cell Signaling), and actin (New England Biolabs Ltd
and Sigma-Aldrich). Detection was by ECL (GE Healthcare/Amersham)
using a HRP-linked secondary Ab. Bcr-Abl activity was determined as
described previously.27
Assessment of apoptosis and CFSE tracking of cell division
Apoptosis and CFSE tracking were performed as previously described.16,17,28
High-resolution cell-cycle analysis
High-resolution cell-cycle analysis was performed using Ki-67 and 7AAD
(BD Biosciences).29
CFC and LTC-IC assays
Colony forming cell (CFC) and LTC-IC were performed as previously.28
Q-PCR for Bcr-Abl and Abl-kinase domain mutation analyses
Quantitative PCR (Q-PCR) was performed by standardized Europe Against
Cancer (EAC) protocols30 and final results expressed according to the
international scale.31 Kinase domain mutation was investigated by direct
sequencing.32,33
Q-PCR
Isolation of DNase-treated RNA was performed using RNeasy Mini or
Micro Kits (QIAGEN). For colony PCR, cDNA was made using the
TaqMan Gene Express Cells-to-CT Kit (Ambion). Bcr-Abl was detected
using a real-time TaqMan assay (Eurogentec) or Evergreen (Web Scientific)
using the ABI 7500 Fast Real-Time PCR system (Applied Biosystems).
GAPDH was used as control, setting the cutoff at 35 cycles.
Mice and genotyping
Genotyping of SCLtTA/Bcr-Abl dtg mice was described previously.2
Approval for the animal research was obtained from the local authorities of
North-Rhine (Westphalia, Germany). For first-round transplantation, 2 106
BM cells were tail vein injected into 12-week-old FVB/N CD45.2 mice
after 8 Gy irradiation. For secondary transplantation, 1.2  106 FACS-
sorted CD45.1 cells were injected into 9 Gy irradiated FVB/N CD45.2
recipients. Mice were treated with cotrimoxazole (Ratiopharm) until
2 weeks after transplantation. Peripheral blood (PB) was collected from the
retro-orbital plexus. Tissues were fixed with 5% paraformaldehyde/PBS
and paraffin-embedded. Sections from spleen were stained using N-acetyl-
chloroacetate esterase (NACE).
Flow cytometry analysis of mice
After red cell lysis, cells were stained with CD45.1, CD45.2, CD3, B220,
Gr1, CD41, Ter119, IgG2a, and IgG2b (BD Biosciences) and CD11b
(Invitrogen). FACS analysis for LineageSca-1c-kit (LSK) cells was
performed using red cell–lysed BM stained with rat Abs specific for CD3,
CD4, CD8a, B220, and Gr1 (Invitrogen), CD11b, Ter119. LSK cells were
stained using CD117 (c-kit) and Sca-1 (BD Biosciences). Isolation of
lineage-negative cells was performed using MACS mouse lineage depletion
kit (Miltenyi Biotec Inc). For purification of LSK cells, lineage-negative
cells were stained with rat Abs specific for CD3, CD4, CD8a, B220, and
Gr1 (Invitrogen), CD11b, Ter119, CD117 (c-kit), and Sca-1 (BD Biosci-
ences) and FACS-sorted.
Statistical analysis
Error bars represent SEM. Statistical analyses were performed using the
2-tailed Student t test. A level of P  .05 was taken to be statistically
significant.
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Results
Leukemic stem cells retain their transplantation and
leukemogenic potential after complete reversion of Bcr-Abl
We previously described an inducible transgenic mouse model of
CML in which p210-Bcr-Abl expression is targeted to stem and
progenitor cells of murine BM using the tet-off system.2,8 On
tetracycline withdrawal, Bcr-Abl expression is induced and mice
demonstrate leukocytosis, splenomegaly, and myeloid hyperplasia.
The disease is transplantable using Bcr-Abl unfractionated (uf)
BM or LSK cells and can be reverted after tetracycline treatment or
to a much lesser extent using imatinib.8 In both transgenic and
primary transplant recipients, the CML-like disease is fatal after
29-122 days.2,8
Here we used the CD45.1/45.2 system to discriminate donor
and host cells in a transplantation setting and were thus able to
serially transplant the initially leukemic cells after abrogation of
Bcr-Abl expression and reversion of the CML phenotype (Figure
1Ai). SCLtTA/Bcr-Abl double-transgenic (dtg) BM cells from
CD45.1 donors were transplanted into 8Gy sublethally irradiated
CD45.2 recipients (n  12). Wild-type (wt) CD45.1 donors were
used as controls (n  12). An alternative approach would have
been to use dtg mice as donors and to maintain one cohort on and
the other one off tetracycline throughout the experiment. This was
considered but decided against in view of concern that tetracycline
might lead to undesired effects on either normal or leukemic
hemopoiesis. Recipient mice were maintained off tetracycline to
induce Bcr-Abl expression as shown previously.2,8 PB analysis on
day 21 confirmed that dtg recipient mice had developed disease and
this was confirmed in BM and spleen on day 25 when mice were
killed. At this time point, donor BM LSK showed a slight but
significant 1.2-fold expansion compared with controls (supplemen-
tal Figure 1A-G, available on the Blood Web site; see the
Supplemental Materials link at the top of the online article).
Figure 1. CML stem cells retain transplantation and oncogenic capacity following Bcr-Abl reversion. (A) Irradiated CD45.2 mice (8 Gy) transplanted using
unfractionated (uf) CD45.1 BM cells isolated from SCLtTA/Bcr-Abl dtg or wt controls (n  12/12). (i) Bcr-Abl expression in recipient mice was controlled by absence
(expression) or presence (no expression) of tetracycline in drinking water. Bcr-Abl expression was induced after transplantation for 25 days and the phenotype analyzed in dtg
and controls (n  3/3) by FACS of BM and spleen cells, spleen weight and histology, ratio of donor:host LSK cells, and Bcr-Abl expression. (ii) Bcr-Abl expression was reverted
for 48 days and a cohort of remaining mice (n  4/4) analyzed. (iii) BM cells from reverted dtg and controls were retransplanted using CD45.1 FACS-sorted cells (n  5/5).
Bcr-Abl expression was reinduced and the phenotype was assessed 69 days after retransplantation. (Bi-ii) PB was analyzed in CD45.1 retransplanted and reinduced mice
34 days after secondary transplantation. FACS of (C) BM and (D) spleen. Mean percentages of donor cells (CD45.1), recipient cells (CD45.2), granulocytes (Gr1/CD11b),
immature granulocytes (Gr1low/CD11b), donor granulocytes (Gr1/CD45.1), immature donor granulocytes (Gr1low/CD45.1), B cells (B220), T cells (CD3), or erythroid
cells (Ter119). Spleen weights on (E) autopsy, (F) spleen histology, (G) donor:host ratio within BM LSK, and (H) Bcr-Abl expression in secondary recipients. (I) BM and LSK
cells from 4-week induced dtg and control mice were cultured with either 50nM dasatinib, 100nM dasatinib, or DMSO for 48 hours. The level of p-CrkL was measured by
Western blotting. (J) Apoptosis in total BM, Gr1, and LSK cells was assessed by annexin V staining in cells from 4-week induced dtg (n  7) and control (n  5) mice that were
treated for 48 hours using 100nM dasatnib or DMSO. Histologic analyses of spleen were performed using NACE stain and are shown at magnifications of (insets) 10 and
20. Shown is 1 representative spleen histology from each group. LF indicates lymphoid follicle. Data represented as mean SEM; *P  .05.
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Tetracycline was then administered to the remaining mice to
abrogate Bcr-Abl expression and revert the phenotype (Figure
1Aii). By day 41 on PB sampling the disease had been completely
reverted with no difference between dtg and controls (supplemental
Figure 1Hi-ii) and this was confirmed at the time of sacrifice on day
48, with no evidence of leukemia in BM or spleen (supplemental
Figure 1I-M). Strikingly, the percentages of mature and immature
granulocytic donor cells decreased to control levels in dtg BM and
spleen on Bcr-Abl abrogation (compare supplemental Figure 1B-C,
I-J), showing that proliferation and survival of mature cells are
affected by Bcr-Abl abrogation. Conversely, BM LSK donor cells
had continued to increase by equivalent amounts in control and dtg
mice (supplemental Figure 1M) suggesting that dtg donor LSK
cells showed similar chimerism dynamics as controls. Bcr-Abl was
neither detectable in total BM nor spleen cells, nor in FACS-sorted
CD45.1 BM cells from either cohort. Histology of spleen showed
no evidence of leukemic infiltration and there was no evidence of
splenomegaly. To assess potential residual Bcr-Abl expression in
reverted LSK cells, we FACS-sorted these cells from a cohort of
primary, transgenic mice that had either been induced for 3 weeks
or reverted for an additional 6 weeks. Analysis of BM, spleen, and
PB confirmed neutrophilia and splenomegaly restricted to induced,
but not reverted dtg or control mice (supplemental Figure 2A-B).
RT-PCR using LSK cells showed a 	 96% reduction of Bcr-Abl
expression in reverted mice back to control levels (supplemental
Figure 2C). To assess Bcr-Abl activity, we performed Western blot
using lineage-negative BM cells from mice that had either been
induced for 4 weeks (supplemental Figure 2E) or mice that had
been reverted for 68 days after a 3-week induction period (supple-
mental Figure 2F). Level of CrkL phosphorylation was increased
on induction of Bcr-Abl (supplemental Figure 2E) but was
decreased to control level on reversion (supplemental Figure 2F).
These results confirmed that by administration of tetracycline the
leukemic phenotype had been completely reverted.
As a final step, FACS-sorted, BM-derived, CD45.1 cells from
each cohort were retransplanted, at 1.2  106 cells/mouse, into
9 Gy sublethally irradiated, secondary recipients (CD45.2, n 5/5,
Figure 1Aiii). These mice were maintained off tetracycline to
reinduce Bcr-Abl expression to determine whether cells with
oncogenic potential had survived the reversion period. PB analyses
34 days after transplantation again showed an increased donor-to-
host cell ratio, increasing percentages of donor granulocytes
(Figure 1Bi) and increased numbers of granulocytes (Figure 1Bii).
After a further 35 days, the secondary recipients were killed at
69 days after retransplantation and reinduction of Bcr-Abl expres-
sion. CD45.1 dtg donor cells had engrafted in BM and spleen
(Figure 1C-D). Although the phenotype was weaker than in the
primary recipients, there was still significant expansion of imma-
ture myeloid donor cells in BM and spleen (Figure 1C-D).
Development of splenomegaly was observed, but did not reach
statistical significance (Figure 1E), unless the dtg mice were
corrected for loss of body weight on disease development. In
addition, disruption of spleen morphology and myeloid cell
infiltration of the spleen were clearly observed in dtg mice (Figure
1F). There was a nonsignificant trend toward an increase of dtg
donor BM LSK compared with control LSK cells (2.1-fold
increase, Figure 1G). Bcr-Abl was expressed in BM and spleen of
all secondary dtg recipients (Figure 1H). As an alternative to
switching off Bcr-Abl transgene expression in transplanted CD45.1
dtg LSK, we treated total BM and LSK cells with dasatinib.
Western blot showed that p-CrkL level was increased in total BM
and LSK of Bcr-Abl–expressing cells but was completely reverted
on 100nM dasatinib treatment (Figure 1I). In addition we demon-
strated that dasatinib treatment significantly induced apoptosis in
leukemic total BM and mature Gr1-positive cells, whereas Bcr-Abl–
expressing dtg LSK were comparatively resistant (Figure 1J).
Partial Bcr-Abl knockdown inhibits proliferation of CML
CD34 cells
Recently Shah et al argued for evaluation of more than one end
point for inhibition of Bcr-Abl to ensure coverage of an adequate
dynamic range.34 Measurement of inhibition of phosphorylation of
STAT5 and CrkL by flow cytometry and Western blotting was
therefore optimized in BaF3 cells expressing Bcr-Abl (supplemen-
tal Figure 3A-C). A total of 150nM dasatinib reduced phosphoryla-
tion of both CrkL and STAT5 to the baseline seen in parental BaF3
cells, with no effect on Bcr-Abl T315I mutant and no additional
effect with increasing concentrations of dasatinib (supplemental
Figure 3A-C). Previous data using lentiviral-mediated shRNA
delivery confirmed efficient and specific knockdown of Bcr-Abl in
Ph cell lines expressing B3A226,35 (supplemental Figure 3D-E).
Here Bcr-Abl was knocked down in CML CD34 cells expressing
B3A2, cultured in SFM supplemented with physiologic growth
factors, and viral transduction of the most primitive CD3438
population verified (supplemental Figure 4A-B). To measure the
extent of Bcr-Abl knockdown, transduced CD34 CML cells were
FACS sorted. Q-PCR confirmed 56% specific down-regulation of
Bcr-Abl mRNA (Figure 2A) and Western blot showed clear
reduction in Bcr-Abl protein level (48% by densitometry; Figure
2B). We then sought to demonstrate inhibition of Bcr-Abl down-
stream targets. In primary CML CD34 cells, 150nM dasatinib was
sufficient to reduce p-CrkL27 and p-STAT5 to the same level
(described as baseline) as non-CML CD34 cells (Bcr-Abl-
negative control; Figure 2C-D). In Bcr-Abl knockdown, CML cell
inhibition of phosphorylation of both CrkL and STAT5 was
observed in CD34 and CD3438 cells by flow cytometry (gated
on GFP cells; supplemental Figure 4C), and in CD34 cells for
STAT5 by Western blotting (Figure 2B), although the level of
inhibition was not as profound as seen with dasatinib.
While sh-Control expressing cells were able to expand
 3-fold
over 12 days in the presence of physiologic growth factors,
sh-Bcr-Abl cells showed little expansion (Figure 3A), with some
induction of apoptosis (Figure 3B). To examine the effect of
Bcr-Abl knockdown on survival/proliferation of functional CML
stem and progenitor cells, GFP cells were plated into CFC and
LTC-IC assays (Figure 3C-D). Bcr-Abl knockdown resulted in
47% and 71% reduction in CFC and LTC-IC colonies, respectively.
Q-PCR on single colonies for Bcr-Abl and Western blotting for
p-CrkL on pooled colonies confirmed Bcr-Abl inhibition in cells
expressing sh-Bcr-Abl (Figure 3E-F).
A proportion of CML CD34 cells is sensitive to enhanced
levels of Bcr-Abl inhibition
To determine whether CML CD34 cells would be susceptible to
further inhibition of Bcr-Abl activity, GFP knockdown and
control cells were cultured in physiologic growth factors in the
presence and absence of 150nM dasatinib for 12 days, with fresh
medium and dasatinib replaced on days 4 and 8. When GFP CML
CD34 cells were exposed to 150nM dasatinib (Figure 2E-F),
further reductions in phosphorylation of CrkL and STAT5—over
those seen with sh-Bcr-Abl, and to previously described baseline
levels—were seen, confirming complete inhibition of Bcr-Abl
kinase activity. For dasatinib, cell counts on days 4, 8, and 12 illustrated
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a sharp reduction in cell numbers evident by day 4, irrespective of
Bcr-Abl knockdown (Figure 3A). Most interestingly, 
 50% of input
cells survived combined partial Bcr-Abl knockdown and dasatinib
treatment for 12 days, indicating that, at least in medium supplemented
with physiologic growth factors, a proportion of CD34 cells can
survive without Bcr-Abl kinase activity. However, with the limited
number of cells available it was not feasible to confirm complete
Bcr-Abl inhibition at all time points, neither was it possible to examine
whether, as expected, surviving cells were enriched for primitive
stem cells.
Complete Bcr-Abl kinase inhibition is achievable at the
stem/progenitor cell level
To investigate in more detail whether CML stem/progenitor cells
would be susceptible to complete inhibition of Bcr-Abl activity,
CML CD34 cells were cultured in SFM, in the presence or
absence of dasatinib, which was replaced with fresh medium on
days 4 and 8. After preliminary experiments (supplemental Figure
5A-D, supplemental Table 1), these cells were cultured without
growth factors to exclude any additional survival signals. In the
remaining viable cells on days 4, 8, and 12 Bcr-Abl activity was
fully inhibited as demonstrated by complete inhibition of p-CrkL
by flow cytometry and by Western blotting (Figure 4A-B). Because
genuine CML stem cells likely represent a small fraction of total
CD34 cells, previous work has focused on those CD34 cells that
remain quiescent in culture by tracking cell division with
CFSE.16,17,28 Here the level of inhibition of p-CrkL by continuous
exposure to dasatinib 150nM was determined on days 4, 8, and 12 for
viable CML CD34 cells that remained undivided in culture or
entered cell divisions 1, 2, or 3. The level of inhibition of p-CrkL
achieved across the entire time course showed no significant
difference for primitive undivided CD34 CML cells compared
with more mature cells able to enter division (Figure 4C, supplemen-
tal Table 2). Inhibition of p-STAT5 by dasatinib gave a very similar
profile as seen for p-CrkL (supplemental Figure 6A). Although no
significant differences were detected in levels of inhibition between
undivided and cells in divisions 1-3, we repeated the experiment
including a higher concentration of dasatinib to ensure that
inhibition of p-CrkL was complete (Figure 4D). Critically, residual
levels of p-CrkL were equivalent for 150 and 1000nM dasatinib.
The most primitive, quiescent CML stem and progenitor cells
are independent of Bcr-Abl kinase for survival
In the mouse, hemopoietic stem cells can be selected to near purity
(1 in 2) based on surface markers. However, this is not yet possible
for normal or leukemic human stem cells. The human stem and
progenitor compartment should therefore be considered as a
continuum and not made up of discrete populations. Here we have
combined accepted surrogate markers for primitive cells based on
phenotype, CFSE retention, absence of Ki-67 staining, expansion
kinetics, CFC, CFC replating, and LTC-IC to demonstrate which
CML cells are growth factor and Bcr-Abl kinase independent. Over
Figure 2. Bcr-Abl knockdown and dasatinib treatment
of CML cells in physiologic growth factors. CD34
CML cells were infected with sh-Bcr-Abl or sh-Control.
(A) Forty-eight hours following second infection, cells
were sorted for GFP and RNA, protein extracted, and
relative expression of Bcr-Abl measured by Q-PCR (n  5,
P  .0004) and (B) Bcr-Abl and p-STAT5 by Western
(n  1). CD34 non-CML (n  3) and CML cells (n  3)
were cultured in SFM  growth factors  150nM dasat-
inib. Twenty-four hours after treatment, (C) p-CrkL and
(D) p-STAT5 were measured by flow cytometry. Lentivi-
rally infected CD34 cells (n  3) were cultured in physi-
ologic growth factors and treated  150nM dasatinib.
Twenty-four hours after treatment, (E) p-CrkL and
(F) p-STAT5 were measured in infected cells (gated on
GFP) cells by flow cytometry.
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the same 12 days, in the absence of growth factors, untreated CML
CD34 cells expanded by
 4-fold, in keeping with their autocrine
production of cytokines,36,37 whereas with 150nM dasatinib viable
cells decreased to 10% of input (Figure 5A). CFSE profiling
demonstrated that even in the absence of growth factors and with
addition of dasatinib, CML CD34 cells were able to enter
divisions 1 and 2, with a few cells progressing as far as division
3 (Figure 5B). The untreated control CML CD34 cells proliferated
more actively, with the majority of cells found in divisions 3 and 4.
Although CFSE profiling confirmed that most CML CD34 cells
had gone through one or more divisions in the presence of
dasatinib, by day 12,	 85% of residual cells had become quiescent
Figure 3. Functional analysis of CML CD34 cells
following Bcr-Abl knockdown  dasatinib. (A) Prolif-
eration of GFP sorted cells treated  150nM dasatinib
in physiologic growth factors over 12 days (n  3).
(B) Apoptosis measured in infected cells (gated on GFP)
by annexin V and viaprobe (n  2). (C) CFC (n  4,
P  .025) and (D) LTC-IC assays (n  1). (E) Bcr-Abl
levels were measured by Q-PCR on colonies from CFC
assay (n  7 colonies for sh-scrambled and 9 colonies for
sh-Bcr-Abl). (F) The level of total p-CrkL was measured
by Western blotting on pooled colonies from CFC assay
(n  1).
Figure 4. Complete Bcr-Abl inhibition is achieved by
dasatinib within primitive subpopulations of CML
cells. CFSE-stained CD34 CML cells (n  3) were
cultured in SFM  150 or 1000nM dasatinib for 12 days.
(A) The levels of total p-CrkL were measured by flow
cytometry and (B) by Western blotting at day 12. p-CrkL
was also measured within each cell division after treat-
ment with either (C) 150 or (D) 1000nM dasatinib.
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as demonstrated by low Ki-67 staining (Figure 5Ci-ii). To confirm
that the viable residual cells were functional and not irreversibly
arrested or senescent, on day 12, both experimental arms were
washed and reestablished in culture in SFM with added growth
factors. Ki-67 and 7AAD analysis confirmed that the majority of
CML CD34 cells that had been cultured in the absence of growth
factors and in the presence of dasatinib at 150nM for 12 days
rapidly entered cell division with only 6% remaining Ki-67 low
after a further 7 days of culture (Figure 5Ciii-iv). The pattern of
Ki-67 and 7AAD staining was very similar for the untreated control
(Figure 5Ciii-iv). Further confirmation that almost all the dasatinib-
treated cells entered cell division again by day 7 was provided
through CFSE staining (Figure 5Di-ii). Although the residual
quiescent fraction was  10% in both arms, the dasatinib-treated
cells expanded more slowly over 7 days with a total 5-fold
expansion compared with untreated control, 17-fold expansion
(Figure 5E). Both populations showed complete reactivation of
Bcr-Abl kinase activity, as measured by p-CrkL staining (data not
shown). Enrichment for primitive cells was confirmed by CFSE
retention, phenotyping for CD34 and CD133 (Figure 5F) and by
residual CFC, CFC replating potential, and LTC-IC activity in the
dasatinib-treated cells (Figure 5G-K). Considering that the un-
treated cells expanded by 4-fold and the dasatinib-treated cells
decreased to 10% of input, the final frequency of LTC-IC was
10-fold higher in the dasatinib-treated versus untreated arms. The
residual viable cells present at day 12 were also confirmed to
express single copy Bcr-Abl by D-FISH (Figure 5L), to express
Bcr-Abl by Q-PCR (supplemental Figure 6B) and showed no
evidence of mutation by direct sequencing of the kinase domain,
thus confirming that these cells were leukemic and that their
dasatinib resistance could not be explained by mutation.
Discussion
The discovery that Bcr-Abl exhibited oncogenic properties38 and
was sufficient to induce CML-like disease in mice1 provided clear
evidence that Bcr-Abl was the key initiating event in CML.
However, for many years investigators were skeptical that a tumor
would remain dependent on the initiating oncogene in view of
accumulation of additional genetic and epigenetic events occurring
over time. The early studies with imatinib, a relatively selective
Bcr-Abl inhibitor, resulted in a genuine paradigm shift with many
drug discovery efforts now focused on single oncogenic lesions and
the belief that a variety of tumors may depend on the driver
oncogene. This concept of oncogene addiction was further strength-
ened when CML patients with blast crisis, a cancer more akin to solid
tumors, also showed dramatic responses to imatinib, providing
Figure 5. A primitive subset of CD34 CML cells survives complete Bcr-Abl inhibition in growth factor–free medium for 12 days. (A) CD34 CML cells (n  3) were
cultured in SFM  150nM and viable cell counts performed on days 4, 8, and 12, and (B) percentages of cells residing within each cell division determined by CFSE staining.
After 12 days, cells were washed with PBS, added to CFC and LTC-IC assays, cultured in SFM plus high growth factor cocktail for 7 days. At day 7, (C) Ki-67/7AAD and
(D) CFSE were measured by flow cytometry and (E) viable cell counts performed. (Ci) Cells at day 12 without drug treatment; (ii) cells at day 12 following dasatinb treatment;
(iii) cells from (i) cultured for additional 7 days in SFM plus high growth cocktail; and (iv) cells from (ii) cultured for additional 7 days in SFM plus high growth factor cocktail.
(Di) Cells from panel Ci were cultured for additional 7 days in SFM plus high growth factor cocktail, and (ii) cells from panel Cii were cultured for additional 7 days in SFM plus
high growth factor cocktail. (F) The relative increase in CD34CD133CFSEhigh was calculated (n  3, P  .001) and the numbers of (G) CFC (n  7, P  .048) and
(H) LTC-IC (n  3, P  .025) per 1000 cells at day 12 were calculated. The changes in (I) CFC, (J) CFC replated (n  2), and (K) LTC-IC numbers compared with baseline cells
(1.0) were also calculated. (L) The presence of Bcr-Abl (denoted by the white arrows) was measured by D-FISH in the remaining CML cells following the 12 day time course.
A representative profile from (i) non-CML CD34 cells at baseline, (ii) untreated CD34 CML cells and (iii) 150nM dasatinib-treated CD34 cells is demonstrated.
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compelling proof that even these genetically complex cancers can
remain dependent on the initiating driver mutation. The phenom-
enon of oncogene addiction, while well recognized, is poorly
understood. Despite genetic complexity cancer cells become
dependent, by an unknown mechanism, on a single oncoprotein-
driven signaling cascade, which, if disrupted acutely, results in
cell-cycle arrest and apoptosis. There is ongoing debate regarding
whether this is a passive process resulting from withdrawal of
prosurvival signaling, or an active process driven by accumulation
of proapoptotic signals.39-41 Furthermore, responses of tumors to
oncogene inhibition are highly variable and dependent on the
cellular and genetic context. These responses in human cancer are
paralleled in transgenic murine models in which oncogene inactiva-
tion gives the impression of tumor regression, yet on oncogene
reactivation the disease can recur.2,8,42,43
For CML, there is now convincing evidence that the malignant
stem cell population is intrinsically resistant to kinase inhibi-
tors13,14,16-19,25 and behaves quite differently to the bulk population
of more mature cells that are oncogene addicted. This also appears
to be the case in the transgenic mouse model in which Bcr-Abl
mature myeloid cells undergo apoptosis in response to in vitro
dasatinib treatment, with the LSK population being relatively
resistant. In vivo Bcr-Abl is likely induced in 
 50% of donor
CD45.1 long-term repopulating HSCs, 20% of LSK and 17% of
linc-kit cells based on a comparable model using the SCL 3
enhancer44 and unpublished data (R.B., 2011). This fits well with
our data showing that on reversion of the leukemic phenotype the
proportion of donor CD45.1 cells returns to those of control mice
rather than being eliminated altogether. We considered that rever-
sion of disease in this model may either occur because transgenic
stem cells undergo apoptosis in response to oncogene inactiva-
tion39-41 or because they revert back to the behavior of normal stem
cells and no longer produce excess numbers of more mature
myeloid cells. Our data show that despite complete reversion of
disease the leukemic LSK persist, but proliferate less, and do not
undergo apoptosis on oncogene withdrawal. These surviving LSK,
in which Bcr-Abl expression has been suppressed by 	 96%, are
capable of reinitiating disease after secondary transplantation and
reinduction of Bcr-Abl expression.
These results with the transgenic CML model were closely
replicated by our work on primary CML cells. Functional CML
stem and progenitor cells were able to survive in vitro for
prolonged periods of time despite complete oncogene inactivation
and withdrawal of cytokines. Using similar experimental ap-
proaches to Corbin et al,25 we made every effort to demonstrate that
in the surviving CML stem cells Bcr-Abl activity was completely
shut off. We further confirmed that the drug-resistant population
belonged to the leukemic clone, was enriched for primitive cells,
and showed neither Bcr-Abl amplification nor kinase domain
mutation, further mechanisms that might explain their resistance.
Taken together, these results have firmly shifted our focus
toward Bcr-Abl kinase–independent resistance mechanisms that
might involve stem cell phenotype, stem cell signaling, or other
survival pathways that are either not suppressed by or are induced
by kinase inhibitors and are the subject of current investigation by
ourselves and others. These involve approaches to (1) reverse CML
stem cell quiescence by interfering with Foxo transcription factor
activity using inhibitors of TGF, BCL6 activity using a retro-
inverso peptide inhibitor,45,46 or promyeloctic leukemia protein
activity using arsenic trioxide; (2) inhibit self-renewal in favor of
differentiation through inhibition of WNT or hedgehog signaling;
(3) mobilize CML stem cells from the niche using CXCR4
antagonists; (4) inhibit JAK signaling; (5) inhibit kinase inhibitor–
induced autophagy; (6) activate PP2A; or (7) exploit differences in
epigenetic regulation between normal and CML stem cells. These
approaches have been comprehensively reviewed.47
When considering mechanisms of resistance, it is important to
consider both the kinase activity of Bcr-Abl and other nonkinase
domains of Bcr-Abl that might confer resistance. Using a mouse
genetics approach, Chen et al were able to reveal Alox5 as a target
whose expression was dependent on Bcr-Abl expression, but not
modulated by kinase inhibition.48 To take account of this possibil-
ity, we used the combination of Bcr-Abl knockdown with kinase
inhibition. However, because we were unable to achieve 	 50%
inhibition of Bcr-Abl using an shRNA specific for the breakpoint
and believe that this is not technically possible in primary CML
stem cells at this time, we have not formally been able to exclude
ongoing signaling via nonkinase Bcr-Abl motifs or proteins within
the Bcr-Abl interactome such as Jak2, within the primary cells.49,50
Although complete abrogation of Bcr-Abl expression was achieved
in the transgenic mouse model, we accept that relatively short-term
transgenic expression may not allow for further genetic or epige-
netic changes that likely occur in the primary setting that might
affect the degree of oncogene addiction and would again suggest
caution comparing mouse models with human disease. Future
efforts toward cure in CML patients who are responding well to
kinase inhibitors, but continue to show evidence of minimal
residual disease, should focus on understanding the mechanisms of
proliferation arrest and dormancy on oncogene inactivation in the
CML stem cell population and aim to target Bcr-Abl kinase–
independent survival pathways that remain active in these cells or
are activated on kinase inhibition. In the latter scenario, it is
possible that kinase inhibition will be required alongside a second
agent to achieve synthetic lethality. Similarly, in solid tumors
driven by a single oncogene and sustained by cancer stem cells an
enhanced understanding of tumor dormancy will be a critical step
to uncovering novel targets in this drug-resistant population.
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